Literature DB >> 3966668

Verapamil: placental transfer and effects on maternal and fetal hemodynamics and atrioventricular conduction in the pregnant ewe.

S H Murad, K M Tabsh, K A Conklin, G Shilyanski, F Ziadlourad, P A Kapur, W E Flacke.   

Abstract

Verapamil may have application in the field of obstetrics for treatment of maternal and fetal tachyarrhythmias. This study was performed to assess the maternal and fetal hemodynamic effects of this drug, as well as to determine its placental transfer and effects on maternal and fetal atrioventricular conduction in the pregnant ewe. Verapamil, 0.2 mg/kg, administered intravenously over 3 min, resulted in a transient decrease in maternal mean and diastolic blood pressures. There was, however, no significant change in fetal systolic, diastolic, and mean blood pressures. Maternal and fetal heart rates also were unchanged throughout the experiment. Atrioventricular conduction, assessed by measurement of PR intervals, was prolonged in both the ewe (41%) and the fetus (78%). Placental transfer of verapamil was limited, as shown by the umbilical vein to uterine artery drug concentration ratios of 0.35-0.45 throughout most of the experiment. Fetal hepatic extraction of the drug appeared to be substantial, since the drug concentration in the fetal carotid artery was less than that of the umbilical vein at 1, 3, and 5 min after drug injection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966668

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

Review 1.  The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.

Authors:  G M Mitani; I Steinberg; E J Lien; E C Harrison; U Elkayam
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

Review 2.  Fetal Arrhythmia Diagnosis and Pharmacologic Management.

Authors:  Janette F Strasburger; Gretchen Eckstein; Mary Butler; Patrick Noffke; Annette Wacker-Gussmann
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.